Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees17
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.02. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.23 million. Geron had a negative net margin of 3,713.04% and a negative return on equity of 17.53%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
4 brokers have issued 12 month target prices for Geron's shares. Their forecasts range from $1.80 to $4.00. On average, they expect Geron's share price to reach $3.0125 in the next twelve months. This suggests a possible upside of 98.2% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
Media headlines about GERN stock have been trending somewhat positive on Thursday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Geron earned a news impact score of 1.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting Geron?
Geron saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 43,290,319 shares, an increase of 1.2% from the April 15th total of 42,790,023 shares. Based on an average daily trading volume, of 2,236,233 shares, the short-interest ratio is presently 19.4 days. Currently, 23.3% of the company's stock are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Turning Point Therapeutics (TPTX), Theravance Biopharma (TBPH), Eidos Therapeutics (EIDX), Amphastar Pharmaceuticals (AMPH), Clementia Pharmaceuticals (CMTA), Inflarx (IFRX), Ra Pharmaceuticals (RARX), Deciphera Pharmaceuticals (DCPH), Radius Health (RDUS), Athenex (ATNX), Homology Medicines (FIXX), Alder Biopharmaceuticals (ALDR), Omeros (OMER), Rhythm Pharmaceuticals (RYTM) and Axovant Sciences (AXON).
What other stocks do shareholders of Geron own?
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
- Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
- Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
- Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)
Who are Geron's major shareholders?
Geron's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.86%), Geode Capital Management LLC (1.17%), Northern Trust Corp (1.16%), Charles Schwab Investment Management Inc. (0.56%), Metropolitan Life Insurance Co NY (0.24%) and SG Americas Securities LLC (0.23%). Company insiders that own Geron stock include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Virtu Financial LLC and Northern Trust Corp. Company insiders that have sold Geron company stock in the last year include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.
Which major investors are buying Geron stock?
GERN stock was purchased by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co NY, SG Americas Securities LLC, Geode Capital Management LLC, Bienville Capital Management LLC, Charles Schwab Investment Management Inc., BlueMountain Capital Management LLC, MetLife Investment Advisors LLC and MetLife Investment Advisors LLC. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.52.
How big of a company is Geron?
Geron has a market capitalization of $283.50 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
